Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (516)	3/7/2005 11:34:30 AM
From: Icebrg	of 946

Clearly, they will have to refinance again. The question is whether they can do this on the strength of good Pixantrone results or not. Or an amendment of the Stellar 4 SPA. It's a pity so little is known about the Xyotax results. It would have been interesting to know, if this was just one of those one in five events the trial was powered to miss or if there was no treatment effect at all. Or rather, if there was a treatment effect, but not one superior to the one of paclitaxel. I guess we will not learn more until ASCO, unless there is indeed a positive treatment effect and Stellar 4 proves this. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next